Shares of Eli Lilly and Company (NYSE:LLY) have earned a consensus rating of “Hold” from the twenty-three research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $88.44.
Several analysts recently issued reports on LLY shares. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. Piper Jaffray Companies reissued a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Monday, April 17th. Argus downgraded Eli Lilly and from a “buy” rating to a “hold” rating and raised their price target for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reissued a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a report on Sunday, May 21st.
In related news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Over the last quarter, insiders sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Canandaigua National Bank & Trust Co. boosted its stake in Eli Lilly and by 5.2% in the second quarter. Canandaigua National Bank & Trust Co. now owns 10,062 shares of the company’s stock worth $828,000 after buying an additional 493 shares in the last quarter. Penserra Capital Management LLC boosted its stake in Eli Lilly and by 13.0% in the second quarter. Penserra Capital Management LLC now owns 2,288 shares of the company’s stock worth $188,000 after buying an additional 264 shares in the last quarter. Great Lakes Advisors LLC boosted its stake in Eli Lilly and by 112.7% in the second quarter. Great Lakes Advisors LLC now owns 33,707 shares of the company’s stock worth $2,774,000 after buying an additional 17,860 shares in the last quarter. Usca Ria LLC purchased a new stake in Eli Lilly and during the second quarter worth approximately $621,000. Finally, Strategic Financial Group LLC boosted its stake in Eli Lilly and by 4.0% in the second quarter. Strategic Financial Group LLC now owns 3,899 shares of the company’s stock worth $321,000 after buying an additional 150 shares in the last quarter. Institutional investors and hedge funds own 75.61% of the company’s stock.
Eli Lilly and (NYSE:LLY) traded down 0.29% on Monday, hitting $82.07. The stock had a trading volume of 2,769,747 shares. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The company’s 50 day moving average price is $82.99 and its 200-day moving average price is $81.53. The company has a market cap of $86.58 billion, a price-to-earnings ratio of 35.51 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.86 EPS. Equities research analysts anticipate that Eli Lilly and will post $4.16 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Eli Lilly and’s dividend payout ratio is currently 90.04%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
